Aerie Pharmaceuticals Inc
Most Recent
Array BioPharma: Why Wall Street Analysts Are Positive
Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”
What Analysts Recommend for Array BioPharma Stock
As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.
